Product Description
Dolasetron is used to prevent nausea and vomiting caused by cancer chemotherapy. Dolasetron is in a class of medications called serotonin 5-HT3 receptor antagonists. It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. (Sourced from: https://medlineplus.gov/druginfo/meds/a601001.html)
Mechanisms of Action: 5-HT3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Canada | Chile | Colombia | Germany | Ireland | Italy | Morocco | New Zealand | Pakistan | Peru | Sweden | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|